Tag Archive for: Biocomposites

Weekly wrap-up: $100m Series B financing for a bivalent vaccine, to new clinical data from a cutting-edge antibody-drug conjugate…

/in

Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine  Vicebio Ltd, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, on Monday announced a $100 million Series B financing  led by TCGX  with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio,  and participation from UniQuest and founding investor Medicxi.  London-based Vicebio said funding […]

Read more

Biocomposites acquires remaining shares in manufacturers of SYNICEM™ and Subiton products

/in

SYNICEM™ and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers support surgeons’ infection treatment strategiesLaboratorios SL S.A. and Synergie Ingénierie Médicale S.A.R.L. are the manufacturers of SYNICEM™ and Subiton products Keele, UK, 18 September 2024 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone […]

Read more

Biocomposites to distribute its NanoBone® product range in the UK

/in

• NanoBone® is a next-generation osteoinductive bone graft consisting of patented nanostructured hydroxyapatite for remodelling bone • Biocomposites to introduce NanoBone at the British Orthopaedic Association’s Annual Congress in Birmingham Keele, UK, 12 September 2024 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating bone and managing infection […]

Read more

From $1bn deals to Smart RNA – read our news roundup

/in

AstraZeneca buys Novo Holdings portfolio company Amolyt in potential $1bn+ deal Novo Holdings A/S and Sofinnova Partners, two leading life sciences investors, made headlines on Thursday when portfolio company Amolyt Pharma entered into a definitive agreement to be acquired by AstraZeneca at a purchase price of US$800 million upfront and a potential milestone payment of […]

Read more

Biocomposites announces two new Phase II clinical trials of STIMULAN VG – a calcium matrix antibiotic carrier mixed with vancomycin and gentamicin – in the U.S.

/in

BLADE-VG2 trial will evaluate the safety and efficacy of STIMULAN VG to treat diabetic foot osteomyelitis BLADE-OPU2 will evaluate the safety and efficacy of STIMULAN VG to treat stage IV pressure ulcers Keele, UK, 7 February 2024 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management […]

Read more